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Abstract
Aims: Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer.
The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and current practice
was not previously known. A national survey was commissioned to investigate the landscape of IMRT use for rectal cancer and to inform the development of
national rectal cancer IMRT guidance.
Materials and methods: Aweb-based survey was developed by the National Rectal Cancer IMRT Guidance working group in collaboration with the Royal College
of Radiologists and disseminated to all UK radiotherapy centres. The survey enquired about the implementation of IMRT with a focus on the following aspects of
the workflow: dose fractionation schedules and use of a boost; pre-treatment preparation and simulation; target volume/organ at risk definition; treatment
planning and treatment verification. A descriptive statistical analysis was carried out.
Results: In total, 44 of 63 centres (70%) responded to the survey; 30/44 (68%) and 36/44 (82%) centres currently use IMRT to treat all patients and selected
patients with rectal cancer, respectively. There was general agreement concerning several aspects of the IMRT workflow, including patient positioning, use of
intravenous contrast and bladder protocols. Greater variation in practice was identified regarding rectal protocols; use of a boost to primary/nodal disease;
target volume delineation; organ at risk delineation and dose constraints and treatment verification. Delineation of individual small bowel loops and daily
volumetric treatment verification were considered potentially feasible by most centres.
Conclusion: This survey identified that IMRT is already used to treat rectal cancer in many UK radiotherapy centres, but there is heterogeneity between centres
in its implementation and practice. These results have been a valuable aid in framing the recommendations within the new National Rectal Cancer IMRT
Guidance.
 2020 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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In patients with locally advanced rectal cancer, radio-
therapy has been shown to significantly reduce the risk of
locoregional recurrence [1e6].
Recently, preoperative (chemo)radiotherapy for rectal
cancer has been increasingly delivered using intensity-
modulated radiotherapy (IMRT). However, the extent of
IMRT use in the UK for rectal cancer has been unclear and no
consensus previously existed regarding its implementation.
Given these uncertainties, the potential complexities of an
IMRT workflow and the lack of a national strategy, a
multidisciplinary working group was formed from radio-
therapy centres across the UK to develop the National Rectal
Cancer IMRT Guidance [7].
In order to inform guidance development and aid the
framing of specific recommendations, the working group
commissioned a national survey of radiotherapy centres.
The objectives of the survey were to describe the current
use and delivery of IMRT, to illustrate areas of consensus
and heterogeneity in the IMRT pathway and to understand
the feasibility of particular recommendations contained
within the draft guidance document.Materials and Methods
The survey was developed using a web-based platform
(Survey Monkey) by members of the working group and
an internal pilot by seven members was carried out to
ensure content validity prior to dissemination.
For centres not currently using IMRT, the survey explored
the reasons for this and asked respondents whether a na-
tional guidance document would aid IMRT implementation.
For these respondents, the survey ended after these ques-
tions were completed. For those centres currently using
IMRT, the survey questions corresponded to sections con-
tained within the proposed national guidance. The dose
fractionation questions primarily concerned ‘long course’
radiotherapy (LCRT) but all other sections were applicable
to both ‘short course’ radiotherapy (SCRT) and LCRT. These
survey sections included: dose fractionation schedules and
use of a boost; pre-treatment preparation and simulation;
target volume/organ at risk (OAR) definition; treatment
planning and treatment verification. Importantly, the sur-
vey asked centres how they treated the majority of the
patients with rectal cancer managed within a curative
intent pathway. For clarity and to aid data analysis, tick box
answers were provided for each question where possible,
with the use of free text boxes kept to a minimum. A copy of
the final survey can be found in the Appendix.
The survey invitation was disseminated via e-mail on 27
February 2020 to the audit leads at all radiotherapy centres
in the UK with the instructions that it should be completed
by the clinical lead for rectal cancer radiotherapy in
collaboration with a medical physicist and therapeutic
radiographer. The survey was open for 4 months. A
reminder e-mail was sent to non-responding centres after 6weeks and individual approaches to complete the survey
were made by members of the working group.
Descriptive statistics were carried out using Microsoft
Excel2016.Thenumbersofcentres responding toeachanswer
for each questionwere expressed as a percentage of the total.
The surveywas led by two clinical oncology trainees (CRHand
FS) supported by senior members of the working group.Results
Current Use of Intensity-modulated Radiotherapy for Rectal
Cancer
In total, 70% (44/63) of centres responded to the survey.
Most respondents (36/44, 82%) indicated that they use
IMRT to treat selected patients with rectal cancer and 68%
(30/44) indicated that they use IMRT to treat all patients
with rectal cancer. Volumetric modulated arc therapy was
the most common method of IMRT delivery (31/36, 86%).
Dose Fractionation Schedules
The survey specifically addressed LCRT dose fraction-
ation schedules. For those centres currently using IMRT to
treat rectal cancer patients, the most commonly used
schedule for the elective lymph node irradiation during
preoperative LCRT was 45 Gy in 25 fractions (31/36, 86%).
Some centres indicated that they use more than one dose
fractionation schedule. Ten centres (28%) use 50.4 Gy in 28
fractions and seven centres (19%) use 50 Gy in 25 fractions.
Nevertheless, all 12 centres who indicated that they
routinely use more than one elective dose fractionation
schedule highlighted that 45 Gy in 25 fractions was their
most commonly used schedule.
In total, 25 centres (25/36, 69%) routinely deliver a boost
in selected patients, with seven centres (7/36, 19%) doing
this for all or nearly all patients. The dose fractionation
schedules used to deliver boost treatments are shown in
Figure 1 and indicate use of both sequential and simulta-
neous integrated boost (SIB) delivery. In those centres that
reported use of a boost for all or nearly all patients, this is
carried out using a SIB in all cases. In contrast, concerning
centres in which a boost is delivered only to selected pa-
tients, both sequential and SIB delivery was reported. None
of the centres reported use of a boost in excess of 54 Gy.
Pre-treatment Preparation and Simulation
Of centres that currently use IMRT, most (33/36, 92%) plan
and treat patients in the supine position. Most centres (81%)
administer intravenouscontrastwith thesimulationcomputed
tomography scan for all patients and six (17%) centres use
intravenous contrast only for selectedpatients. One centre (3%)
indicated that they donot use intravenous contrast at all. Small
bowel contrast is used by only 14 centres (39%).
In total, 34 of 36 centres (94%) use a bladder protocol for
the simulation computed tomography scan. Overall, 27
centres (27/36, 75%) indicated that they use a protocol of
Fig 1. Boost technique and dose fractionation schedules used by UK radiotherapy centres currently using intensity-modulated radiotherapy (n ¼
25). ‘All or nearly all’ and ‘selected’ were the definitions used in the survey. Interpretation of these definitions was left to the discretion of the
responding centre. SIB, simultaneous integrated boost.
Fig 2. Sources used to guide radiotherapy target volume definition.
Thirty-one centres use a specific clinical trial protocol/guideline (n ¼
21 ARISTOTLE alone [8]; n ¼ 2 Valentini et al. [9] alone; n ¼ 7
ARISTOTLE [8] and Valentini et al. [9]; n ¼ 1 ARISTOTLE [9], Valentini
et al. [9] and Roels et al. [10]).
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ment, one centre (1/36, 3%) indicated that they carry out a
planning scan with an empty bladder and six centres (6/36,
17%) use a protocol that is distinct from either of these ap-
proaches. Overall, 26 centres (26/36, 72%) indicated that
they verify bladder filling during treatment. Specifically, 14
centres (14/36, 39%) use cone beam computed tomography
(CBCT) image verification, five centres (5/36, 14%) use ul-
trasound and four centres (4/36, 11%) indicated that they
use a mixture of CBCT and ultrasound.
Overall, 21 of 36 centres (58%) currently using IMRT
indicated that they have a rectal protocol for simulation (in
four centres asking patients to open bowels prior to simu-
lation; in 16 taking action based on the computed tomog-
raphy scout view; and in one specifically using a micro-
enema if rectal diameter was over 4 cm on computed to-
mography simulation). Twelve centres (12/36, 33%) re-
ported that they attempt to maintain a rectal protocol
during treatment, with nine of these centres (9/36, 25%)
specifically reporting the use of CBCT monitoring followed
by intervention if rectal filling is problematic.
Target Volume Definition
All 36 centres currently using IMRT indicated that they
use a protocol to guide target volume definition, with 31
centres (31/36, 86%) referencing a specific clinical trial
protocol/guideline. Figure 2 illustrates the referenced trialprotocols/guidelines and indicates that 31 centres (31/36,
86%) use the ARISTOTLE clinical trial protocol [8]. Table S1
summarises the major differences in target volume delin-
eation between ARISTOTLE and the new guidance and
Figure 3 illustrates the differences in the elective clinical
Fig 3. Planning computed tomography images at a similar axial level in the pelvis showing the elective clinical target volume delineated as per
(A) the ARISTOTLE trial protocol [8] and (BeD) the new guidance [7]. In (A), a 7 mm margin around the internal iliac vessels determines the
borders for the elective clinical target volume, which has a flat anterior border, at this level. In the new guidance, at this level a highly conformal
volume is created by the following steps illustrated in (BeD). (B) A 7 mm margin in all directions (except in the superioreinferior direction) is
applied to the internal iliac vessels, inferior mesenteric artery and superior rectal vessels at this level. (C) A 10 mm rollerball is used to join these
volumes together. (D) The volume is edited off muscle and bone.
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In total, 18 centres (18/36, 50%) stated that they have
developed their own local target volume protocol by
adapting a previously published protocol (in eight centres
based on ARISTOTLE [8]; in four based on ARISTOTLE [8] and
Valentini et al. [9]; in two based on Valentini et al. [9] alone;
in one based on ARISTOTLE [8], Valentini et al. [9] and Roels
et al. [10]; in three trial not specified). One centre indicated
they had developed their own local protocol without
adapting any previous guideline and one centre indicated
that their local protocol was developed using the rectal
cancer IMRT protocol from a different UK radiotherapy
centre. Overall, only 39% (14/36) of centres currently using
IMRT indicated that they have routine peer review of rectal
cancer target volume contours.
All 36 centres currently using IMRT indicated that mag-
netic resonance imaging (MRI) is employed in some capacity
to aid target volume and OAR delineation. Specifically, 23
centres (23/36, 64%) use the diagnosticMRI side by sidewith
simulation computed tomography, ten (10/36, 28%) use a co-
registered diagnostic MRI scan and one (1/36, 3%) uses a
radiotherapy-specific MRI scan co-registered with the
planning computed tomography scan. One centre (1/36, 3%)
indicated that a radiotherapy-specific MRI was carried out ifrequested by the treating consultant and one centre (1/36,
3%) indicated that a diagnostic MRI was co-registered only if
requested by the treating consultant. No centres currently
use an MRI-only planning pathway.
Organ at Risk Definition
Figure 4 illustrates the OARs routinely delineated in
centres currently using IMRT. Fourteen centres (14/36, 39%)
outline individual small bowel loops and 12 centres (12/36,
33%) outline a ‘bowel space’/peritoneal cavity structure.
Four centres (4/36, 11%) indicated that they outline both of
these structures. Ten centres (10/36, 28%) indicated that
they delineate another type of bowel structure and these
variations included individual small and large bowel loops
as a single structure and the external contour of groups of
bowel loops but including the space between loops (‘bowel
bag’ as per EMBRACE II clinical trial) [11]. Two centres (2/36,
6%) reported that they do not routinely contour any bowel
structure.
For the purposes of treatment planning and/or plan
evaluation, 31 centres (31/36, 86%) currently using IMRT
utilise OAR dose constraints. The remaining five centres (5/
36,14%) indicated that although they do not use constraints,
Fig 4. Organs at risk outlined routinely in centres currently using intensity-modulated radiotherapy (n ¼ 36). The number (y-axis) corresponds
to the number of centres in which a particular structure is outlined and adds up to greater than 100% as multiple structures are outlined at each
centre. Three centres reported delineation of ‘other’ structures, which included stoma (where present) and bone.
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those 31 centres that do use OAR constraints, 18 (18/31, 58%)
indicated that these constraints were derived from a clinical
trial protocol (ARISTOTLE [8], nine centres; RTOG 0822 [12],
three centres; PLATO [13], three centres; trial not specified,
three centres). Other reported sources for OAR constraints
included the National Anal Cancer IMRT Guidance [14],
Quantec guidelines [15], Valentini et al. [9], historical data
from that centre, and unspecified gynaecology/genitouri-
nary cancer radiotherapy guidelines.
Image-guided Radiotherapy and Treatment Verification
Table 1 tabulates the on-treatment imaging modalities
used by the 36 centres currently using IMRT.
Exploratory Questions
Two exploratory questions regarding contouring of
bowel structures and image guidance were included within
the survey to address the most contentious issues within
the working group discussions. All centres, including those
not currently using IMRT, were invited to respond to these
questions.
Thirty-four of 44 centres (77%) indicated that it would be
potentially feasible to implement routine delineation of
individual small bowel loops. Despite agreeing that this
would be potentially feasible, eight centres indicated that
there might be barriers to this implementation in their freetext responses and six centres (6/44, 14%) were uncertain
whether it would be feasible. Of those six centres, three are
not currently using IMRT and two are not currently out-
lining any bowel structure. Of the four remaining centres (4/
44, 9%) that responded that it would not be feasible to
implement routine delineation of individual small bowel
loops, three currently outline a peritoneal cavity/‘bowel
space’ structure. Concerns raised within free text comments
relating to proposed implementation of small bowel loop
delineation included time/resource constraints and a lack of
evidence to support the use of this method over other
bowel structures.
Thirty-one of 44 centres (70%) indicated that imple-
mentation of daily CBCT image guidance for LCRT would be
potentially feasible. Eight centres (8/44, 18%) indicated that
they were not sure if implementation of daily CBCT image
guidance would be feasible. Of these, five centres are not
currently using IMRT, two are using a ‘no action limit’ pro-
tocol and one carries out imaging on the first three to five
fractions only. Of the remaining five centres (5/44, 11%) that
reported it would not be feasible, three are currently using a
‘no action limit’ protocol and one centre is not using IMRT.Centres not Currently Using Intensity-modulated
Radiotherapy
Eight of 44 centres (18%) indicated that they are not
currently using IMRT routinely for the treatment of patients
with rectal cancer. Three of these eight centres indicated
Table 1
Frequency of use for various on-treatment imaging technologies and frequency of imaging and whether centres changed imaging frequency
when they adopted intensity-modulated radiotherapy (IMRT) for the treatment of rectal cancer. The total number exceeds the 36 centres
currently using IMRT as in some centres multiple imaging modalities are used
Number (n ¼ 36) Percentage (rounded)y
Modality
2D kV alone 1 3%
CBCT alone 20 56%
CBCT and 2D kV 11 31%
CBCT and 2D kV/MV mix 2 6%
CBCT and on-board imaging 1 3%
CBCT and MRI 1 3%
Frequency of imaging (and if there was a change in protocol when centres switched from 3D conformal treatment to IMRT)
Daily 19 53%
Change 13 (13/19, 68%)
No change 6 (6/19, 32%)
‘No action limit’ protocol* 16 44%
Change 12 (12/16,75%)
No change 4 (4/16, 25%)
First three to five fractions only 1 0%
Change 1 (1/1. 100%)
No change 0 (0/1, 0%)
2D, two-dimensional; 3D, three-dimensional; CBCT, cone beam computed tomography; kV, kilovoltage; MRI, magnetic resonance imaging;
MV, megavoltage.
* ‘No action limit’ protocol: first three to five fractions then weekly.
y Percentage may not add to 100% due to rounding.
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time of their survey response, one centre indicated that
implementation had been halted due to the COVID-19
pandemic and four centres suggested that there was an
insufficient evidence base to prioritise IMRT implementa-
tion. Five centres indicated that national guidance would
help with future IMRT implementation and all eight
responded that guidance would be useful to inform dose
fractionation schedules. Recommendations concerning OAR
definition, treatment planning and image-guided radio-
therapy were also considered to be valuable.Discussion
This survey has illustrated the current extent to which
IMRT is used in the UK for rectal cancer treatment and the
heterogeneity in its implementation and delivery. Inter-
estingly, 81% of centres that responded to the survey are
already using IMRT in some form. However, it should be
acknowledged that although we consider that the response
rate of 70% provides a good overview of practice throughout
the country, the results of the survey could still be influ-
enced by response bias, in particular from non-responders
who are not currently using IMRT.
This survey represents the first reported comprehen-
sive analysis of IMRT use for rectal cancer in the UK. A
previous analysis of the Radiotherapy Dataset and Na-
tional Cancer Data Repository concerned data from the
era before IMRT was widely adopted in the UK [16]. Data
describing IMRT use from the National Cancer Registra-
tion and Analysis Service (NCRAS) suggest that about 60%of rectal cancer radiotherapy treatments were with IMRT
in 2018e2019, which may be comparable with our find-
ings for IMRT use if non-responding centres are taken
into consideration [17]. There are limited data concerning
IMRT use for rectal cancer internationally. Two analyses
of the National Cancer Database and National Compre-
hensive Cancer Network (NCCN) Colorectal Cancer Data-
base in the USA were recently reported, although these
studies examined data from 2005e2015. The authors
concluded that although the utilisation of IMRT was
increasing in the USA, there remained considerable vari-
ability in its uptake. Wegner and colleagues [18] esti-
mated that IMRT use was 22% in the USA in 2014, based
on an analysis of the National Cancer Database, and
Reyngold et al. [19] reported that IMRT treatments at
designated NCCN centres represented 38% of all rectal
cancer treatments in 2011.
This survey has indicated that there is good consensus
among UK centres regarding several aspects of the IMRT
treatment pathway, including supine positioning, admin-
istration of intravenous contrast and use of bladder filling
protocols. All centres reported that they useMRI as an aid in
target volume delineation, but few centres use computed
tomography/MRI fusion or carry out a radiotherapy-specific
MRI.
During the development of the National Rectal Cancer
IMRT Guidance, there were several aspects for which it was
challenging to secure consensus within the working group
due to a lack of existing high-level evidence. In these in-
stances, the survey provided useful information regarding
current practice to inform the guidance recommendations.
The main issues are outlined below.
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The survey indicated that nearly 70% of centres are
already using a boost for at least some patients with rectal
cancer, with 60% delivering this as a SIB and 36% using doses
>50 Gy. Twenty-eight per cent of centres currently use a
sequential boost. Taking these survey results into account,
and in order to maximise the potential resource benefits of
IMRT, including reduced planning time and fewer treat-
ment fractions, the guidance working group have suggested
using a SIB rather than a sequential boost. In addition, an SIB
may improve patient outcomes as shown in other tumour
types [20,21]. The optional boost dose in the guidance is 50
Gy. Given the evidence for a doseeresponse relationship in
rectal cancer, in selected patients or sites of disease where
the aim is complete pathological response (e.g. an organ
preservation strategy or where pathologically involved
nodes are outside of the TME volume), doses >50 Gy can be
considered [21e23]. Doses >50 Gy have been examined
within several phase II studies, which appear to show
acceptable acute toxicities and promising pathological
complete response rates, although there remains an
absence of phase III data [24e26]. The guidance states that
it is at the discretion of individual centres whether they
choose to deliver doses exceeding 50 Gy in clinical scenarios
where the goal is complete response. We would suggest a
SIB of 52 Gy based on a small series showing minimal acute
toxicity [21].
(ii) Rectal protocol
Although nearly 60% of centres that responded to the
survey indicated that they currently make attempts to
minimise rectal filling at simulation, only one third attempt
to maintain this during treatment. It has been shown that
there is considerable internal organ motion and deforma-
tion of the rectum and mesorectum during radiotherapy,
which provides the rationale for attempting to standardise
rectal volume at simulation and during treatment, espe-
cially when a SIB is used during LCRT [27,28]. A suggested
rectal protocol is therefore included within the national
guidance.
(iii) Target volume definition
All centres currently using IMRT that responded to the
survey have a protocol to guide target volume definition,
but the references for these protocols varied. The ARIS-
TOTLE trial protocol [8] was cited by 21 centres as a source
for target volume delineation guidance. However, the
ARISTOTLE trial used a three-dimensional conformal
radiotherapy technique, with target outlines encompassing
significant volumes of normal tissue [8]. Although not
specifically addressed within this survey, it is possible that
some centres currently using IMRT, especially those using
ARISTOTLE-based protocols, may not be optimising treat-
ments to IMRT-specific target volumes. This may negate the
potential benefits of IMRT regarding target dose con-
formality and reduction in dose to OAR. The guidanceprovides recommendations for IMRT-specific target vol-
umes (and inverse planning optimisation), which represent
a departure from those used in the ARISTOTLE trial. The
final volumes included in the guidance were based on a
synthesis of clinical trial protocols, consensus guidelines,
in-house departmental protocols, a survey of variations in
clinical target volumes with rectal cancer staging and a
project examining the most reliable method for identifying
the superior border of the elective volume during the
guidance development [9,12,29]. A comprehensive litera-
ture review was undertaken to inform the guidance rec-
ommendations for planning target volume margins that
account for internal motion and other sources of error and
whether daily or a ‘no action limit’ protocol for treatment
verification is to be used [30]. With the use of highly
conformal target volumes, routine use of quality assurance
of radiotherapy contours is of critical importance. Only 39%
of centres reported that they are currently using routine
peer review of contours, despite recommendations from the
Royal College of Radiologists regarding peer review for
rectal cancer radiotherapy within a curative intent treat-
ment pathway [31]. As a result, the guidance makes a spe-
cific recommendation regarding implementation of routine
quality assurance for target volume delineation.
(iv) Small bowel delineation
There was considerable discussion within the working
group regarding delineation of individual small bowel loops
versus a ‘bowel cavity’ structure. Heterogeneity in practice
was also identified in the survey, with several approaches to
bowel contouring described, including not delineating a
bowel structure at all. This variable approach to bowel
contouring reflects a lack of data on the optimal bowel
structure to delineate in order to predict and reduce early
and late bowel toxicities [15,32,33]. Most centres (77%)
considered that delineation of individual bowel loops
would be potentially feasible, although we note the com-
ments regarding time and resource implications, as well as
limited evidence within the literature as to the optimum
approach. Several centres specifically suggested that
training radiographers, dosimetrists or physicists to
contribute to OAR outlining may be a potential solution to
resource constraints. Although there was a strong desire
within the working group to recommend a single approach
to small bowel delineation, no majority consensus in favour
of either delineation of individual bowel loops or ‘bowel
cavity’ could be reached. As a compromise, the guidance
recommends small bowel loops with dose constraints based
on the RTOG 0822 trial [12]. However, alternative delinea-
tion instructions and constraints for a ‘bowel cavity’ struc-
ture are also included within an Appendix in the National
Rectal Cancer IMRT Guidance.
(v) Organ at risk dose constraints
Few IMRT-specific OAR constraints are reported within
the literature for rectal cancer, especially for SCRT deliv-
ering 25 Gy in five fractions. This is particularly relevant
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been an increased use of SCRT (with or without sequential
neoadjuvant chemotherapy) as an alternative to LCRT [34].
The survey indicated that centres are currently using a va-
riety of sources for OAR constraints, including the National
Anal Cancer IMRT Guidance [14] and anal cancer clinical
trial protocols as well as the ARISTOTLE protocol [8] (which
did not actually contain OAR constraints) [8,9,12e15]. The
working group noted that OAR constraints from the Na-
tional Anal Cancer IMRT Guidance were already in general
use and therefore decided to use these as a basis for many of
the guidance recommendations [14]. For SCRT, no robust
recommendations could be found in the literature; instead,
in-house constraints from two UK centres were included in
the guidance, as these were known to work in clinical
practice.
(vi) Treatment verification
Although 70% of centres considered that implementation
of daily CBCT would potentially be feasible, several re-
spondents highlighted the potential resource implications
of such a recommendation. The guidance therefore man-
dates daily online CBCT for SCRT and recommends daily
online imaging with CBCT for LCRT delivered with IMRT.
Acknowledging that this recommendation may not be
feasible in all centres, two sets of recommended planning
target volume margins for LCRT are provided for a daily and
a ‘no action limit’ protocol, respectively.
Heterogeneity in the use of radiotherapy for rectal cancer
treatment during the pre-IMRT era was demonstrated in an
anslysis of the Radiotherapy Dataset and National Cancer
Data Repository[16]. This study showed there was variation
between NHS Trusts in England regarding whether radio-
therapy was used, what type of radiotherapy was delivered
(short course versus long course) and the time interval
between radiation and surgery. The authors suggested that
this variation in clinical decision making between multi-
disciplinary teams across England might be explained by
differing levels of confidence and expertise among surgeons
and radiologists. Since then, the evidence base for the
optimal use of radiotherapy has continued to develop
[16,35] and in recent years, a radiotherapy modernisation
programme has taken place across the UK. This programme
has encouraged the adoption of IMRT, but there has not
been clear national guidance on its optimal implementation
for rectal cancer [36,37]. It is possible that an absence of
national guidance may account for some of the variation in
practice demonstrated in our survey. This ongoing hetero-
geneity in IMRT use provides a rationale for attempting to
harmonise practice by implementing national guidance. It
will be important to evaluate the impact of the guidance on
patient outcomes, for example using NCRAS data or national
audits such as those carried out following publication of the
National Anal Cancer IMRT Guidance [17,38e40]. These
types of evaluations would allow comparison of clinical
practice alongside clinicopathological and outcome data
and provide the clearest understanding of whether practice
has changed and the impact this has had on patient care.In summary, the survey results reported in this paper
have provided valuable insight into the current landscape of
IMRT use for rectal cancer in the UK and have helped frame
the recommendations contained in the first version of the
National Rectal Cancer IMRT Guidance [7]. We hope that the
National Rectal Cancer IMRT Guidance will encourage
implementation of IMRT in all centres across the UK and
help to harmonise the variation in practice identified by the
survey. We plan to undertake a further survey following
release of the guidance to evaluate the impact of its rec-
ommendations and to inform development of further ver-
sions of the guidance.Conflicts of Interest
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